MergerMay 11, 2026, 04:13 PM
Lisata Therapeutics Merger with Kuva Labs Delayed; Going Concern Doubt
AI Summary
Lisata Therapeutics announced that the tender offer for its acquisition by Kuva Labs Inc. has been extended to May 29, 2026, with an explicit statement that there is no assurance the offer will commence. Concurrently, the company disclosed substantial doubt about its ability to continue as a going concern, citing a history of operating losses and negative cash flows, with cash and cash equivalents at $13.06 million. For Q1 2026, Lisata reported a net loss of $4.49 million, a slight improvement from $4.72 million in the prior year, primarily due to reduced research and development expenses.
Key Highlights
- Merger tender offer by Kuva Labs extended to May 29, 2026, with no assurance of commencement.
- Kuva Labs agreed to pay Lisata's expenses up to $1.1 million until the offer commences.
- Management concluded substantial doubt exists regarding Lisata's ability to continue as a going concern.
- Cash and cash equivalents decreased to $13.06 million as of March 31, 2026.
- Q1 2026 net loss was $4.49 million, an improvement from $4.72 million in Q1 2025.
- Research and development expenses fell to $1.20 million from $2.60 million year-over-year.
- Basic and diluted loss per share improved to $(0.50) from $(0.55) year-over-year.
- Net cash used in operating activities decreased to $3.08 million from $5.40 million.